Jump to main content
Jump to site search

Issue 10, 2015
Previous Article Next Article

A shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells

Author affiliations

Abstract

The study reported herein focused on the development and optimization of a versatile analytical methodology for characterization of intracellular distribution of protein-bound species of ruthenium originating from an anticancer Ru-based drug, indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]. A direct analysis of the drug-treated cytosol of cancer cells using size-exclusion chromatography (SEC) interfaced with inductively coupled plasma mass spectrometry (ICP-MS) revealed that over 85% of ruthenium is converted into a high molecular-mass fraction. To further determine the ruthenium binding pattern, a shotgun approach was used, with the entire proteome being digested and the resulting peptides being analyzed by capillary high-performance liquid chromatography (μHPLC) combined with electrospray ionization triple quadrupole MS. This allowed for identification of the ruthenated proteins on the basis of characteristic MS/MS spectra of the respective peptides. It was found that both Ru(III)- and Ru(II)-ligated functionalities participate in adduct formation, the hydrolyzed forms of the drug being attached to the majority of the binding proteins. Of an array of proteins responding to drug treatment, the most important – from the viewpoint of unveiling the exact mode of action – are inhibitor, pro-apoptotic, and DNA reparation proteins.

Graphical abstract: A shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 04 Mar 2015, accepted on 25 Mar 2015 and first published on 25 Mar 2015


Article type: Paper
DOI: 10.1039/C5AN00426H
Analyst, 2015,140, 3492-3499

  •   Request permissions

    A shotgun metalloproteomic approach enables identification of proteins involved in the speciation of a ruthenium anticancer drug in the cytosol of cancer cells

    M. Matczuk, M. Kupiec, J. Legat, K. Pawlak, A. R. Timerbaev and M. Jarosz, Analyst, 2015, 140, 3492
    DOI: 10.1039/C5AN00426H

Search articles by author

Spotlight

Advertisements